Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans

Critical Care Medicine

Volumn 25, Issue 6, 1997, Pages 1079-1082

  Aiuto, Leslie T ^a   Barone, Stephen R ^a   Cohen, Pamela S ^a   Boxer, Robert A ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Alteplase; Disseminated intravascular coagulation; Fibrinolytic agents; Meningococcal infections; Perfusion; Plasminogen activator inhibitor 1; Purpura; Shock, septic; Thrombolytic therapy; Thrombosis

Indexed keywords

ALTEPLASE;

ARTICLE; CASE REPORT; DRUG EFFECT; FULMINATING PURPURA; HUMAN; INFANT; MALE; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MULTIPLE ORGAN FAILURE; ORGAN PERFUSION; PRIORITY JOURNAL; SEPTIC SHOCK;

BLOOD CIRCULATION; HUMANS; INFANT; INFUSIONS, PARENTERAL; MALE; MENINGOCOCCAL INFECTIONS; MULTIPLE ORGAN FAILURE; PURPURA, SCHOENLEIN-HENOCH; RECOMBINANT PROTEINS; SHOCK; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030940870     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199706000-00028     Document Type: Article

References (19)

1. Bohm N: Adrenal, cutaneous and myocardial lesions in fulminating endotoxinemia. Pathol Res Pract 1982; 174:92-105
2. Suffredini AF, Harpel PC, Parrillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:1165-1172
3. Brandtzaeg P, Joo GB, Brusletto B, et al: Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57:271-278
4. Engebretsen LF, Kierulf P, Brandtzaeg P: Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Thromb Res 1986; 42:713-716
5. Pralong G, Calandra T, Glauser MP, et al: Plasminogen activator inhibitor 1: A new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-462
6. Hathaway WW: Heparin therapy in acute meningococcemia. J Pediatr 1973; 82:780-786
7. Fourrier F, Lestavel P, Chopin C, et al: Meningococcemia and purpura fulminans in adults: Acute deficiencies of protein C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16:121-124
8. Gerson WT, Dickerman JD, Bovill EG, et al: Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics 1993; 91: 418-422
9. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682
10. Collen D, Stump DC, Gold HK: Thrombolytic therapy. Annu Rev Med 1988; 39:405-423
11. Marder VJ, Sherry S: Thrombolytic therapy: Current status (first of two parts). N Engl J Med 1988; 318: 1512-1519
12. Zenz W, Muntean W, Gallistl S, et al: Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 1995; 96:141-147
13. Leclerc F, Beuscart B, Guillois JF, et al: Prognostic factors of severe infectious purpura in children. Intensive Care Med 1985; 11:140-143
14. Tesoro LJ, Selbst SM: Factors affecting outcome in meningococcal infections. Am J Dis Child 1991; 145: 218-220
15. Wong VK, Hitchcock W, Mason WH: Meningococcal infections in children: A review of 100 cases. Pediatr Infect Dis J 1989; 8:224-227
16. Algren JT, Suresh L, Cutliff SA, et al: Predictors of outcome in acute meningococcal infection in children. Crit Care Med 1993; 21:447-452
17. McManus ML, Churchwell KB: Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura. Crit Care Med 1993; 21: 706-711
18. Bearman SI, Shuhart MC, Hinds MS, et al: Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80:2458-2462
19. Espigado I, Rodriguez JM, Parody R, et al: Reversal of severe hepatic venoocclusive disease by combined plasma exchange and rt-PA treatment. Bone Marrow Transplant 1995; 16:313-316